Literature DB >> 35065205

Evaluation of immune-modulating drugs for use in drug-eluting microsphere transarterial embolization.

Andrew S Mikhail1, Michal Mauda-Havakuk2, Ayele H Negussie2, Natalie Hong2, Natalie M Hawken2, Camella J Carlson2, Joshua W Owen2, Olga Franco-Mahecha2, Paul G Wakim3, Andrew L Lewis4, William F Pritchard2, John W Karanian2, Bradford J Wood2.   

Abstract

Cancer immunotherapy has yet to reach its full potential due in part to limited response rates and side effects inherent to systemic delivery of immune-modulating drugs. Local administration of immunotherapy using drug-eluting embolic (DEE) microspheres as drug delivery vehicles for direct infusion into tumor-feeding arteries might increase and prolong tumor drug concentrations and reduce systemic drug exposure, potentially improving the risk-to-benefit ratio of these agents. The purpose of this study was to evaluate the ability of four immune modulators affecting two different immune pathways to potentiate replication of immune cells from a woodchuck model of hepatocellular carcinoma. DSR 6434, a Toll-like receptor agonist, and BMS-202, a PD-L1 checkpoint inhibitor, induced immune cell replication and were successfully loaded into radiopaque DEE microspheres in high concentrations. Release of DSR 6434 from the DEE microspheres was rapid (t99% = 0.4 h) upon submersion in a physiologic saline solution while BMS-202 demonstrated a more sustained release profile (t99% = 17.9 h). These findings demonstrate the feasibility of controlled delivery of immune-modulating drugs via a local DEE microsphere delivery paradigm.
Copyright © 2022. Published by Elsevier B.V.

Entities:  

Keywords:  Checkpoint inhibitor; Drug-eluting beads (DEB); Embolization; Hepatocellular carcinoma; Immunotherapy; Woodchuck

Mesh:

Substances:

Year:  2022        PMID: 35065205      PMCID: PMC9139086          DOI: 10.1016/j.ijpharm.2022.121466

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   6.510


  41 in total

1.  Transarterial Chemoembolization in a Woodchuck Model of Hepatocellular Carcinoma.

Authors:  William F Pritchard; David L Woods; Juan A Esparza-Trujillo; Matthew F Starost; Michal Mauda-Havakuk; Andrew S Mikhail; Ivane Bakhutashvili; Shelby Leonard; Elizabeth C Jones; Venkatesh Krishnasamy; John W Karanian; Bradford J Wood
Journal:  J Vasc Interv Radiol       Date:  2020-02-24       Impact factor: 3.464

2.  Single bead investigation of a clinical drug delivery system - A novel release mechanism.

Authors:  E Ahnfelt; J Gernandt; Y Al-Tikriti; E Sjögren; H Lennernäs; P Hansson
Journal:  J Control Release       Date:  2018-11-10       Impact factor: 9.776

3.  Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.

Authors:  Austin G Duffy; Susanna V Ulahannan; Oxana Makorova-Rusher; Osama Rahma; Heiner Wedemeyer; Drew Pratt; Jeremy L Davis; Marybeth S Hughes; Theo Heller; Mei ElGindi; Ashish Uppala; Firouzeh Korangy; David E Kleiner; William D Figg; David Venzon; Seth M Steinberg; Aradhana M Venkatesan; Venkatesh Krishnasamy; Nadine Abi-Jaoudeh; Elliot Levy; Brad J Wood; Tim F Greten
Journal:  J Hepatol       Date:  2016-11-02       Impact factor: 25.083

4.  Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.

Authors:  Andrew X Zhu; Richard S Finn; Julien Edeline; Stephane Cattan; Sadahisa Ogasawara; Daniel Palmer; Chris Verslype; Vittorina Zagonel; Laetitia Fartoux; Arndt Vogel; Debashis Sarker; Gontran Verset; Stephen L Chan; Jennifer Knox; Bruno Daniele; Andrea L Webber; Scot W Ebbinghaus; Junshui Ma; Abby B Siegel; Ann-Lii Cheng; Masatoshi Kudo
Journal:  Lancet Oncol       Date:  2018-06-03       Impact factor: 41.316

5.  New insights into the mechanisms of the interactions between doxorubicin and the ion-exchange hydrogel DC Bead™ for use in transarterial chemoembolization (TACE).

Authors:  Marco Biondi; Sabato Fusco; Andrew L Lewis; Paolo A Netti
Journal:  J Biomater Sci Polym Ed       Date:  2011-01-21       Impact factor: 3.517

Review 6.  Hepatocellular carcinoma in the woodchuck model of hepatitis B virus infection.

Authors:  Bud C Tennant; Ilia A Toshkov; Simon F Peek; James R Jacob; Stephan Menne; William E Hornbuckle; Raymond D Schinazi; Brent E Korba; Paul J Cote; John L Gerin
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

7.  Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma.

Authors:  Firouzeh Korangy; Lars A Ormandy; Jörg S Bleck; Jürgen Klempnauer; Ludwig Wilkens; Michael P Manns; Tim F Greten
Journal:  Clin Cancer Res       Date:  2004-07-01       Impact factor: 12.531

8.  A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead.

Authors:  Ronnie T P Poon; Wai Kuen Tso; Roberta W C Pang; Kelvin K C Ng; Regina Woo; Kin Shing Tai; Sheung Tat Fan
Journal:  Clin Gastroenterol Hepatol       Date:  2007-07-12       Impact factor: 11.382

9.  TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy.

Authors:  Christopher B Rodell; Sean P Arlauckas; Michael F Cuccarese; Christopher S Garris; Ran Li; Maaz S Ahmed; Rainer H Kohler; Mikael J Pittet; Ralph Weissleder
Journal:  Nat Biomed Eng       Date:  2018-05-21       Impact factor: 29.234

Review 10.  Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles.

Authors:  Katarzyna Guzik; Marcin Tomala; Damian Muszak; Magdalena Konieczny; Aleksandra Hec; Urszula Błaszkiewicz; Marcin Pustuła; Roberto Butera; Alexander Dömling; Tad A Holak
Journal:  Molecules       Date:  2019-05-30       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.